Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis.
aetiology
cirrhosis
disease severity
inflammation
malnutrition
proton pump inhibitor
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
10
2019
revised:
13
12
2019
accepted:
07
01
2020
pubmed:
17
1
2020
medline:
22
6
2021
entrez:
17
1
2020
Statut:
ppublish
Résumé
Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment-related factors affect microbiome composition most distinctively. 16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA-effect size and least absolute shrinkage and selection operator regularized regression. Disease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C-reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses. Our cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding. NCT01607528.
Sections du résumé
BACKGROUND & AIMS
Compositional changes of the faecal microbiome in cirrhosis are well described and have been associated with complications and prognosis. However, it is less well known, which disease or treatment-related factors affect microbiome composition most distinctively.
METHODS
16S rDNA sequencing data of 88 cirrhotic outpatients were investigated. Factors influencing microbiome composition were analysed by univariate and multivariate redundancy analysis. The association of the identified factors with changes in diversity and taxonomic composition was studied in depth using analysis of composition of microbiome, LDA-effect size and least absolute shrinkage and selection operator regularized regression.
RESULTS
Disease severity and aetiology, proton pump inhibitor (PPI) use, nutritional status, age and C-reactive protein are significant explanatory variables for faecal microbiome composition in liver cirrhosis. Despite some taxonomic overlaps especially between disease severity and PPI use, we could show that the effects of disease severity, aetiology, PPI use and age are independent factors influencing microbiome composition also in subgroup analyses.
CONCLUSION
Our cross sectional system biology study identifies disease severity, aetiology, PPI use and age as independent factors that influence microbiome composition in liver cirrhosis. In chronic diseases with high morbidity, such as liver cirrhosis, precise patient metadata documentation is of utmost importance in microbiome analysis. Further studies with a higher sample size are necessary to validate this finding.
TRIAL REGISTRATION NUMBER
NCT01607528.
Identifiants
pubmed: 31943691
doi: 10.1111/liv.14382
pmc: PMC7187411
doi:
Substances chimiques
Proton Pump Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT01607528']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
866-877Subventions
Organisme : Austrian Science Fund FWF
ID : P 24362
Pays : Austria
Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Nature. 2018 Mar 29;555(7698):623-628
pubmed: 29555994
Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G951-7
pubmed: 25258407
Hepatogastroenterology. 1984 Feb;31(1):30-4
pubmed: 6698486
J Hepatol. 2019 Jan;70(1):172-193
pubmed: 30144956
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Anaerobe. 2016 Dec;42:55-59
pubmed: 27555373
Dig Dis. 2019;37(2):161-169
pubmed: 30428474
JPEN J Parenter Enteral Nutr. 1987 Jan-Feb;11(1):8-13
pubmed: 3820522
Cochrane Database Syst Rev. 2012 May 16;(5):CD008165
pubmed: 22592727
Transl Res. 2017 Jan;179:49-59
pubmed: 27477080
PLoS One. 2016 May 26;11(5):e0154090
pubmed: 27228093
Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1028-34
pubmed: 27271159
BMC Gastroenterol. 2016 Oct 4;16(1):121
pubmed: 27716148
J Hepatol. 2016 Apr;64(4):813-22
pubmed: 26639396
Nature. 2014 Sep 4;513(7516):59-64
pubmed: 25079328
Front Microbiol. 2016 Dec 20;7:2012
pubmed: 28066342
Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G168-75
pubmed: 21940902
Sci Rep. 2019 Aug 19;9(1):12000
pubmed: 31427714
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
Am J Gastroenterol. 2009 May;104(5):1130-4
pubmed: 19337238
Front Microbiol. 2017 Jun 23;8:1162
pubmed: 28690602
Cell Mol Gastroenterol Hepatol. 2015 May 1;1(3):275-284
pubmed: 26090511
Bioinformatics. 2017 Mar 1;33(5):782-783
pubmed: 28025202
Nutrients. 2019 Feb 19;11(2):
pubmed: 30791484
Aliment Pharmacol Ther. 2016 Nov;44(9):926-935
pubmed: 27593544
Am J Gastroenterol. 2018 Aug;113(8):1177-1186
pubmed: 29872220
Curr Opin Gastroenterol. 2016 May;32(3):159-65
pubmed: 26974417
Nature. 2015 Sep 17;525(7569):E2-3
pubmed: 26381989
PLoS One. 2018 Mar 29;13(3):e0194892
pubmed: 29596512
Gut. 2018 Dec;67(12):2213-2222
pubmed: 30194220
Nutrients. 2019 Jul 11;11(7):
pubmed: 31336737
Science. 2016 Apr 29;352(6285):565-9
pubmed: 27126040
Metab Brain Dis. 2012 Jun;27(2):205-15
pubmed: 22527995
Aliment Pharmacol Ther. 2012 Nov;36(9):866-74
pubmed: 22966967
Hepatology. 2018 Jul;68(1):234-247
pubmed: 29350768
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Am J Physiol Gastrointest Liver Physiol. 2017 May 1;312(5):G413-G419
pubmed: 28232456
Aliment Pharmacol Ther. 2017 Jan;45(2):319-331
pubmed: 27868217
Front Microbiol. 2018 Jun 22;9:1250
pubmed: 29988340
Scand J Clin Lab Invest. 2002;62(4):293-9
pubmed: 12476928
World J Gastroenterol. 2010 Sep 28;16(36):4532-40
pubmed: 20857523
World J Gastroenterol. 2015 Nov 7;21(41):11597-608
pubmed: 26556989
BMC Gastroenterol. 2017 Nov 28;17(1):125
pubmed: 29179682
Hepatology. 2011 Aug;54(2):562-72
pubmed: 21574172
Int J Syst Evol Microbiol. 2006 Aug;56(Pt 8):1985-1990
pubmed: 16902041
Liver Int. 2020 Apr;40(4):866-877
pubmed: 31943691
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Gut. 2011 May;60(5):631-7
pubmed: 21209126
Liver Transpl. 2015 Jun;21(6):753-60
pubmed: 25677965
Nature. 2015 Sep 17;525(7569):E1-2
pubmed: 26381988
J Hepatol. 2017 Nov;67(5):1084-1103
pubmed: 28526488
ISME J. 2011 Feb;5(2):220-30
pubmed: 20686513
Clin Infect Dis. 2018 Aug 31;67(6):869-877
pubmed: 29718124
BMC Med. 2014 Sep 18;12:145
pubmed: 25242656
J Hepatol. 2014 May;60(5):940-7
pubmed: 24374295
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):813-819
pubmed: 28621554
J Hepatol. 2016 Dec;65(6):1232-1244
pubmed: 27515775
Front Microbiol. 2017 Dec 14;8:2508
pubmed: 29312210
Liver Transpl. 2018 Jun;24(6):752-761
pubmed: 29500907
Int J Mol Sci. 2016 Nov 09;17(11):
pubmed: 27834858
Sci Rep. 2016 Oct 04;6:34534
pubmed: 27698480
PLoS One. 2016 May 26;11(5):e0155405
pubmed: 27228122
Clin Gastroenterol Hepatol. 2015 Apr;13(4):753-9.e1-2
pubmed: 25130937
Hepatology. 2015 Oct;62(4):1260-71
pubmed: 25820757
Curr Opin Gastroenterol. 2013 May;29(3):264-70
pubmed: 23493073